RESUMEN
MPV17-related mitochondrial neurohepatopathy is a rare genetic disorder worldwide. We report on a novel pathogenic variant in the MPV17 gene in 24 unrelated neurohepatopathic infants of non-consanguineous Black South African heritage. Exome sequencing identified homozygosity for a c.106C>T nonsense variant in exon 3 of the human MPV17 gene in 2 unrelated index patients. mRNA analysis revealed transcripts both with and without exon 3, indicating both reduced splice efficiency and premature termination as mechanisms for disease. Carrier frequency in this population was found to be 1 in 68 (95% CI; 1/122-1/38) with an estimated newborn incidence of 1 in 18 496 (95% CI; 1/59 536-1/5776). Affected infants all presented with infantile onset neurohepatopathy with none surviving beyond infancy. This description of a relatively common pathogenic variant underlying a previously uncharacterized severe neurohepatopathy in South Africa will engender increased awareness, earlier diagnosis and possibly improve outcome if preventative or specific therapeutic options can be found.
Asunto(s)
Degeneración Hepatolenticular/genética , Proteínas de la Membrana/genética , Mitocondrias/genética , Enfermedades Mitocondriales/genética , Proteínas Mitocondriales/genética , Codón sin Sentido/genética , Femenino , Degeneración Hepatolenticular/patología , Homocigoto , Humanos , Lactante , Masculino , Mitocondrias/patología , Enfermedades Mitocondriales/patología , Sitios de Empalme de ARN/genética , Empalme del ARN , Sudáfrica/epidemiologíaRESUMEN
Letter by Nutten et al. on article by Levin et al. (Levin ME, Blackhurst DM, Kirstein F, Kok D, van der Watt GF, Marais AD. Residual allergenicity of amino acid-based and extensively hydrolysed cow's milk formulas. S Afr Med J 2017;107(9):763-767. S Afr Med J 2017;107(3):258-263. https://doi.org/10.7196/SAMJ.2017.v107i9.12137); and response by Levin et al.
RESUMEN
BACKGROUND: Criteria for labelling infant feeds as suitable for the dietary management of cow's milk protein allergy (CMPA) rely on proving the hypoallergenicity of such feeds or clinical studies showing that the feeds are tolerated by 90% of children with proven CMPA. South African (SA) labelling legislation does not indicate what testing is necessary to prove hypoallergenicity. OBJECTIVES: To evaluate all extensively hydrolysed cow's milk formulas and amino acid-based formulas available in SA for residual allergen content, protein size and amino-acid content. RESULTS: All amino-acid and extensively hydrolysed formulas were found to be similar in composition, with no residual cow's milk allergens detectable by enzyme-linked immunosorbent assay. Furthermore, proteins were absent and only small molecules in the size range of amino acids and possibly of very small oligopeptides were detected. CONCLUSIONS: These findings indicate that the formulas are extremely likely to be compliant with the definition of hypoallergenicity as tolerance in 90% of proven sufferers from cow's milk allergy. The formulas may therefore be labelled as suitable for the dietary management of infants with CMPA.
RESUMEN
BACKGROUND: Evidence suggests that foot problems are common in juvenile idiopathic arthritis (JIA), with prevalence estimates over 90%. The aim of this survey was to describe foot-related impairment and disability associated with JIA and foot-care provision in patients managed under modern treatment paradigms, including disease-modifying anti-rheumatic drugs (DMARDs) and biologic therapies. METHODS: The Juvenile Arthritis Foot Disability Index (JAFI), Child Health Assessment Questionnaire (CHAQ), and pain visual analogue scale (VAS) were recorded in 30 consecutive established JIA patients attending routine outpatient clinics. Foot deformity score, active/limited joint counts, walking speed, double-support time (s) (DS) and step length symmetry index % (SI) were also measured. Foot-care provision in the preceding 12 months was determined from medical records. RESULTS: Sixty-three per cent of children reported some foot impairment, with a median (range) JAFI subscale score of 1 (0-3); 53% reported foot-related activity limitation, with a JAFI subscale score of 1 (0-4); and 60% reported participation restriction, with a JAFI subscale score of 1 (0-3). Other reported variables were CHAQ 0.38 (0-2), VAS pain 22 (0-79), foot deformity 6 (0-20), active joints 0 (0-7), limited joints 0 (0-31), walking speed 1.09 m/s (0.84-1.38 m/s), DS 0.22 s (0.08-0.26 s) and SI +/-4.0% (+/-0.2-+/-31.0%). A total of 23/30 medical records were reviewed and 15/23 children had received DMARDS, 8/23 biologic agents and 20/23 multiple intra-articular corticosteroid injections. Ten children received specialist podiatry care comprising footwear advice, orthotic therapy and silicone digital splints together with intrinsic muscle strengthening exercises. CONCLUSION: Despite frequent use of DMARD/biologic therapy and specialist podiatry-led foot care, foot-related impairment and disability persists in some children with JIA.
Asunto(s)
Artritis Juvenil/epidemiología , Artritis Juvenil/fisiopatología , Enfermedades del Pie/epidemiología , Enfermedades del Pie/fisiopatología , Encuestas Epidemiológicas , Adolescente , Artritis Juvenil/terapia , Niño , Evaluación de la Discapacidad , Femenino , Deformidades Adquiridas del Pie/epidemiología , Deformidades Adquiridas del Pie/fisiopatología , Deformidades Adquiridas del Pie/terapia , Enfermedades del Pie/terapia , Marcha , Humanos , Masculino , Podiatría , Prevalencia , Índice de Severidad de la EnfermedadAsunto(s)
Índice de Masa Corporal , Marcha/fisiología , Niño , Femenino , Humanos , Masculino , Factores de TiempoRESUMEN
BACKGROUND AND PURPOSE: Pharmacokinetic/pharmacodynamic (PK/PD) models are necessary to relate the degree of drug exposure in vivo to target blockade and pharmacological efficacy. This manuscript describes a murine agonist-induced CXCR3 receptor internalization assay and demonstrates its utility for PK/PD analyses. EXPERIMENTAL APPROACH: Activated murine DO11.10 cells were incubated with agonist in the presence or absence of a CXCR3 antagonist and changes in surface CXCR3 expression were detected by flow cytometry. For PK/PD analysis, mice were dosed with a small molecule CXCR3 antagonist, NBI-74330, (100 mg kg(-1)) orally or subcutaneously and plasma samples taken at specified timepoints for the CXCR3 internalization assay. KEY RESULTS: Surface CXCR3 expression was specifically decreased in response to CXCL9, CXCL10 and CXCL11. CXCL11 was the most potent CXCR3 agonist in buffer (pA50=9.23+/-0.26) and the pA50 for CXCL11 was unaltered in murine plasma (pA50=9.17+/-0.15). The affinity of a small molecule CXCR3 antagonist, NBI-74330, was obtained in the absence or presence of plasma (buffer pA2 value: 7.84+/-0.14; plasma pKB) value 6.36+/-0.01). Administration of NBI-74330 to mice resulted in the formation of an N-oxide metabolite, also an antagonist of CXCR3. Both antagonists were detectable up to 7 h post oral dose and 24 h post subcutaneous dose. Measurement of CXCR3 internalization demonstrated significant antagonism of this response ex vivo, 24 h following subcutaneous administration of NBI-74330. CONCLUSIONS AND IMPLICATIONS: The CXCR3 receptor internalization assay provides a robust method for determining agonist potency orders, antagonist affinity estimates and PK/PD analyses, which discriminate between dosing regimens for the CXCR3 antagonist NBI-74330.
Asunto(s)
Acetamidas/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Modelos Biológicos , Pirimidinas/farmacología , Receptores CXCR3/antagonistas & inhibidores , Acetamidas/administración & dosificación , Acetamidas/farmacocinética , Administración Oral , Animales , Quimiocina CXCL10/farmacología , Quimiocina CXCL11/farmacología , Quimiocina CXCL9/farmacología , Sistemas de Liberación de Medicamentos , Citometría de Flujo , Inyecciones Subcutáneas , Masculino , Ratones , Ratones Endogámicos BALB C , Pirimidinas/administración & dosificación , Pirimidinas/farmacocinética , Receptores CXCR3/agonistas , Factores de TiempoRESUMEN
OBJECTIVE: To estimate the prevalence of caseous lymphadenitis (CLA), determine the current usage of vaccines against CLA and to measure the effectiveness of these vaccines on sheep farms. DESIGN AND POPULATION: A survey was undertaken on 223 sheep flocks in New South Wales, Victoria and Western Australia. METHOD: The prevalence of CLA was measured by conventional inspection techniques at abattoirs in lines of sheep that could be traced back to a farm. Managers of the flocks were sent a questionnaire about their vaccine practices, management practices and knowledge of CLA. RESULTS: The average prevalence of CLA in adult sheep in these flocks was 26% and varied from 20% in Western Australia to 29% in New South Wales. About 43% of sheep producers used CLA vaccines; only 12% used them as recommended. Awareness of CLA was highest in Western Australia. More producers would use CLA vaccine if they knew the prevalence of CLA in their flock and producers obtained most information about CLA from vaccine resellers. CONCLUSIONS: Only 10 to 15% of producers are currently achieving effective CLA control through the use of recommended CLA vaccination programs. In Western Australian flocks more than 25% of effectively vaccinated ewes will be sent to abattoirs in the 2 to 3 years after this study. However, large decreases in the prevalence of CLA can be achieved by about 70% of producers by either making adjustments to their vaccination programs or buying a vaccine with a CLA component. Two or three key facts on effective CLA vaccination could be made available at the point of sale of vaccines and from abattoirs that reported the prevalence of CLA to farmers.
Asunto(s)
Vacunas Bacterianas/administración & dosificación , Infecciones por Corynebacterium/veterinaria , Corynebacterium pseudotuberculosis/inmunología , Linfadenitis/veterinaria , Enfermedades de las Ovejas/epidemiología , Enfermedades de las Ovejas/prevención & control , Vacunación/veterinaria , Animales , Infecciones por Corynebacterium/epidemiología , Infecciones por Corynebacterium/prevención & control , Linfadenitis/epidemiología , Linfadenitis/prevención & control , Nueva Gales del Sur/epidemiología , Prevalencia , Ovinos , Enfermedades de las Ovejas/etiología , Encuestas y Cuestionarios , Victoria/epidemiología , Australia Occidental/epidemiologíaRESUMEN
In the course of structural explorations around a series of potent CCK2 receptor antagonists, it was noted that simple N-methylation of the indolic N-H in the parent molecule gave rise to behavior in vivo that was consistent with the compound acting as an agonist. Exploration in vitro confirmed this property, and it was shown that the agonist action could be blocked by the reference CCK2 receptor antagonist, L-365,260. Further examples of this type of modification were explored, and a common theme with regard to agonist behavior was uncovered. Some molecular modeling is also presented in an attempt to throw light on the nature of the ligand receptor interactions that may be giving rise to the differing properties of these, apparently, structurally similar molecules.
Asunto(s)
Adamantano/análogos & derivados , Adamantano/síntesis química , Indoles/síntesis química , Receptores de Colecistoquinina/agonistas , Adamantano/química , Adamantano/farmacología , Animales , Benzodiazepinonas/farmacología , Unión Competitiva , Corteza Cerebral/metabolismo , Técnicas In Vitro , Indoles/química , Indoles/farmacología , Ligandos , Ratones , Modelos Moleculares , Pentagastrina/farmacología , Compuestos de Fenilurea/farmacología , Ensayo de Unión Radioligante , Ratas , Receptor de Colecistoquinina B , Receptores de Colecistoquinina/antagonistas & inhibidores , Receptores de Colecistoquinina/metabolismo , Estereoisomerismo , Estómago/efectos de los fármacosRESUMEN
Mixed hyperlipidaemia is a common finding in glycogen storage disease type Ia (GSD Ia). Although cross-sectional studies have demonstrated increases in intermediate-density lipoproteins (IDLs) and reductions in lipoprotein lipase activity, no studies have investigated the dynamics of apolipoprotein B-100 (apo B) metabolism in GSD Ia. This study investigated apoB turnover in GSD Ia using an exogenous labelling method in one sib from a kinship with established GSD Ia. The study demonstrated normal hepatic secretion of very low-density lipoprotein (VLDL), but hypocatabolism of VLDL, probably due to lack of lipoprotein lipase activity. The production rate of IDL was slightly increased, but the turnover rate of low-density lipoprotein was normal. The findings suggest that, as well as a corn starch diet and dietary fat restriction, treatment of severe mixed hyperlipidaemia in GSD Ia and its attendant risk of pancreatitis should possibly involve fibrates that activate lipoprotein lipase and may enhance the clearance of IDL, rather than omega-3 fatty acids, which principally suppress hepatic secretion of VLDL.
Asunto(s)
Apolipoproteínas B/metabolismo , Enfermedad del Almacenamiento de Glucógeno Tipo I/metabolismo , Lipoproteínas VLDL/metabolismo , Adulto , Apolipoproteína B-100 , Apolipoproteínas B/sangre , Apolipoproteínas B/genética , Glucemia/metabolismo , Carbohidratos de la Dieta , Susceptibilidad a Enfermedades/etiología , Enfermedad del Almacenamiento de Glucógeno Tipo I/dietoterapia , Enfermedad del Almacenamiento de Glucógeno Tipo I/genética , Humanos , Lactatos/sangre , Lipoproteínas/sangre , Lipoproteínas LDL/sangre , Lipoproteínas VLDL/sangre , Lipoproteínas VLDL/genética , Masculino , Almidón/uso terapéuticoRESUMEN
This unit describes three standard in vitro bioassays for studying histamine H1, H2 and H3 receptors in isolated intact tissues removed from the guinea pig. Both the H1 and H3 receptor assays are based on preparations of the ileum, whereas the spontaneously beating right atrium assay is used for the H2-receptor.This unit describes three standard in vitro bioassays for studying histamine H1, H2 and H3 receptors in isolated intact tissue.
Asunto(s)
Íleon/metabolismo , Ensayo de Unión Radioligante/métodos , Receptores Histamínicos/metabolismo , Animales , Cobayas , Agonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos/metabolismo , Técnicas In Vitro , MasculinoRESUMEN
Novel, potent, and selective non-imidazole histamine H(3) receptor antagonists have been prepared based on the low-affinity ligand dimaprit (pK(I) 7.32 +/- 0.12, pK(B) 5.93 +/- 0.17). Detailed structure-activity studies have revealed that N-(4-chlorobenzyl)-N-(6-pyrrolidin-1-ylhexyl)guanidine (pK(I) 8.38 +/- 0.21, pK(B) 8.39 +/- 0.13), 30, and N-(4-chlorobenzyl)-N-(7-pyrrolidin-1-ylheptyl)guanidine (pK(I) 8.78 +/- 0.12, pK(B) 8.38 +/- 0.10), 31, exhibit high affinity for the histamine H(3) receptor. Antagonists 30 and 31 demonstrate significant selectivity over the other histamine, H(1) and H(2), receptor subtypes and a 100-fold selectivity in the sigma(1) binding assay. Compounds 30and 31 are the most potent, selective non-imidazole histamine H(3) receptor antagonists reported in the literature to date.
Asunto(s)
Dimaprit/análogos & derivados , Dimaprit/síntesis química , Guanidinas/síntesis química , Antagonistas de los Receptores Histamínicos/síntesis química , Pirrolidinas/síntesis química , Receptores Histamínicos H3/efectos de los fármacos , Animales , Unión Competitiva , Corteza Cerebral/metabolismo , Dimaprit/química , Dimaprit/farmacología , Diseño de Fármacos , Guanidinas/química , Guanidinas/metabolismo , Guanidinas/farmacología , Cobayas , Antagonistas de los Receptores Histamínicos/química , Antagonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos/farmacología , Íleon/efectos de los fármacos , Íleon/fisiología , Técnicas In Vitro , Ligandos , Contracción Muscular/efectos de los fármacos , Pirrolidinas/química , Pirrolidinas/metabolismo , Pirrolidinas/farmacología , Ensayo de Unión Radioligante , Receptores Histamínicos H1/metabolismo , Receptores Histamínicos H2/metabolismo , Receptores Histamínicos H3/metabolismo , Receptores sigma/metabolismo , Relación Estructura-ActividadRESUMEN
Histamine was converted to a selective histamine H3-receptor antagonist by capping the primary amine with 2-naphthalenesulfonyl chloride. Higher receptor affinity and lower variability in the data from the various bioassays were achieved with the 2-naphthalensulfonamides of histamine homologues.
Asunto(s)
Diseño de Fármacos , Antagonistas de los Receptores Histamínicos/síntesis química , Imidazoles/síntesis química , Receptores Histamínicos H3/química , Sulfonamidas/síntesis química , Animales , Cobayas , Cinética , Modelos QuímicosRESUMEN
1. Since L-365,260 was first described as a selective antagonist at cholecystokinin (CCK)B/gastrin receptors, we have used it periodically as a reference compound in isolated tissue assays of guinea-pig gastric muscle and lumen-perfused stomachs from mouse and immature rat. L-365,260 behaved as a surmountable antagonist and produced parallel rightward shifts of pentagastrin concentration-effect curves' in each of the replicate experiments. The experiments were performed by several different experimenters in the same laboratories over a five year period. 2. In the isolated, lumen-perfused, immature rat stomach assay, L-365,260 behaved as a simple competitive antagonist (Schild plot slope = 1.00 +/- 0.10, pKB = 7.54 +/- 0.03 from a global analysis of the data) acting at a homogeneous population of receptors in five separate, highly-reproducible, experiments. In contrast, the replicate data sets obtained from the interaction in the isolated, lumen-perfused mouse stomach and guinea-pig gastric muscle assays, over the same period, were not consistent with the presence of a single receptor population. The guinea-pig gastric muscle data were relatively reproducible between experiments but some individual Schild plot slopes and the slope estimated from a global analysis of all the data were significantly less than unity (slope = 0.80 +/- 0.07, pA2 = 8.56 +/- 0.05 from the global analysis). The data obtained in the mouse stomach were significantly more variable than that obtained in the same assay, during the same period, from the interaction between histamine and the H2-receptor antagonist, famotidine. The individual Schild plot slopes ranged from being very flat (0.20) to being not significantly different from unity (1.23) and the pA2 values ranged from 7.68 to 8.70. 3. Overall, the data could be accounted for by assuming the variable expression of two receptor subtypes across the assays. The rat stomach appeared to express a single receptor characterized by a low affinity constant for L-365,260 (pKB approximately 7.5). The guinea-pig gastric muscle and mouse stomach data could be explained by the presence of this receptor and a second one characterized by a high affinity constant for L-365,260 (pKB approximately 8.6). The activity of the two proposed receptor subtypes was consistent between experiments in the guinea-pig and the high affinity receptor appeared to be predominant. In contrast, the mouse stomach data could only be simulated by assuming that the proportion and absolute number of each subtype varied significantly between the replicate experiments. 4. The L-365,260 affinity estimates at the inferred receptor subtypes were indistinguishable from those obtained in a corresponding analysis of the behaviour of L-365,260 in CCKB/gastrin receptor radioligand binding experiments in guinea-pig gastric gland and mouse and rat cerebral cortex preparations.